Other languages Neurotech International Limited

Equities

NTI

AU000000NTI9

Market Closed - Australian S.E. Other stock markets 01:34:09 2024-05-27 am EDT			5-day change	1st Jan Change
0.074 ^AUD	0.00%		-1.33%	+7.25%

Apr. 17	Neurotech's Phase II/III NTIASD2 Clinical Trial for Children with Autism Meets Primary Endpoint	MT
Apr. 17	Neurotech International Completes AU$10 Million Capital Raise	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Neurotech International Concludes Phase II/III NTIASD2 Trial for Children with Autism	Apr. 09
Neurotech International Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 26
Neurotech Receives Human Research Ethics Committee Approval to Extend Autism Trial	Feb. 12
Neurotech International Secures Approval to Advance Cerebral Palsy Trial; Shares Rise 6%	Jan. 28
Neurotech International Secures Ethics Approval for Use of Autism Spectrum Medication in Adults	Dec. 04
Neurotech International Secures AU$3 Million R&D Tax Rebate for Fiscal Year 2023	Nov. 14
Neurotech International Completes Enrollment for Rett Syndrome Trial	23-09-26
Neurotech International Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-30
Neurotech International Secures Ethics Approval to Extend Use of Medication in Pediatric Trial	23-05-30
Neurotech International Completes Patient Recruitment for Neuropsychiatric Disorder Treatment Trial	23-05-03
Neurotech International Plans to Launch Phase Two Rett Syndrome Trial	23-03-20
Neurotech International Limited Announces the Launch of A New Clinical Program in Rett Syndrome, Commencement of A Phase II Clinical Trial Investigating the Use of NTI164 in Female Patients	23-03-19
Neurotech International Says Considerable Improvement in ASD Patients Treated with NTI164; Shares Decline 9%	23-03-16
Neurotech International Limited Announces the Final Clinical Results from Eleven Paediatric Autism Spectrum Disorder Patients, Following Daily Treatment of NTI164 over 52 Week Period	23-03-16
Neurotech International Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-28
Neurotech International Limited Announces First Patient Treated in Phase I/II PANDAS/PANS Trial	23-02-15
Neurotech International Secures Ethics Approval to Extend Phase 1/2 Autism Trial	23-02-14
Neurotech International Limited Announces Approval for Additional Phase I/II ASD Trial Extension	23-02-13
Neurotech International Limited Receives HREC Approval for Phase I/II PANDAS/PANS Clinical Trial	23-01-26
Neurotech International Schedules US FDA Meeting for Autism Spectrum Drug	23-01-19

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Neurotech International Limited

Equities

NTI

AU000000NTI9

Other languages

Filters